Mallinckrodt Inc

Mallinckrodt — Debt Investor Presentation (August 2023)

14 slides from Mallinckrodt's debt investor presentation, Aug 23, 2023

  1. Slide 1: Mallinckrodt Pharmaceuticals: Disclosure Materials July 2023

    Mallinckrodt Pharmaceuticals: SUBJECT TO FRE 408, STATE LAW EQUIVALENTS DISCLOSURE MATERIALS July 2023

  2. Slide 2: Disclaimer

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Disclaimer 2 Statements in this document that are not strictly historical, including statements regarding future financial condition and operating results, legal, economic, business, competitive and/or regulator

  3. Slide 3: Disclaimer (cont'd)

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Disclaimer (cont’d) 3 This document contains financial measures, including adjusted EBITDA and unlevered free cash flow, which are considered “non-GAAP” financial measures under applicable SEC rules and regulati

  4. Slide 4: Disclaimer (cont'd): Predecessor and Successor Periods

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Disclaimer (cont’d) 4 Predecessor and Successor Periods Mallinckrodt’s financial results presented here within include Successor and Predecessor periods. The Successor period runs from June 17, 2022 through Marc

  5. Slide 5: Our Primary Focus Remains on Improving Outcomes For Underserved Patients

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Our Primary Focus Remains on Improving Outcomes For Underserved Patients With Severe and Critical Conditions 5 Our Vision Innovation-driven biopharmaceutical company… …focused on improving outcomes for underserv

  6. Slide 6: Diversified Global Specialty Pharma Company

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Diversified Global Specialty Pharma Company 6 2022 Product Mix (% of WholeCo) Segment Highlights Highly Profitable & Strong Forward Visibility Stable & Highly Diversified 2022A Net Sales $1,270MM $645MM Global P

  7. Slide 7: Driving revenue stabilization in 2023 requires mitigation of declining trends for largest brands

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Driving revenue stabilization in 2023 requires mitigation of declining trends for our largest revenue brands ➢ Acthar Gel plan focuses on patient experience and clinical differentiation, defend and improve acces

  8. Slide 8: Specialty Brands Development Pipeline

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Specialty Brands Development Pipeline Preclinical >>>>>> Phase 2 Phase 3 / Registration Commercialized Terlivaz HRS9 Type 1 INOmax HRF8 1. Mechanism of Action; 2. Immune Checkpoint Inhibitors; 3. Full Thickness;

  9. Slide 9: Specialty Generics Strategic Outlook

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Specialty Generics Strategic Outlook 9 ➢ Plan anticipates low single-digit net sales growth for both the API business and the finished generics portfolio ➢ Segment EBITDA remains flat as inflationary and pricing

  10. Slide 10: API and Generics Business Serving Critical Needs of Patients

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS API and Generics Business Serving Critical Needs of Patients 10 Global leader in acetaminophen production, controlled substances, addiction treatment, and ADHD, with vertically-integrated manufacturing ensuring

  11. Slide 11: Consolidated Revenue and Adj. EBITDA Summary

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Consolidated Revenue and Adj. EBITDA Summary 11 ➢ Projected revenue CAGR of +0.7% and projected Adj. EBITDA CAGR of -7.8% over the Strat Plan horizon as competition in both Brands and Generics stabilizes and lau

  12. Slide 12: Consolidated Unlevered Free Cash Flow

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Consolidated Unlevered Free Cash Flow 12 › The Company’s unlevered free cash flow excludes funded debt service and cash taxes › Operational tax rate of ~10%, excluding one-time emergence related tax impacts › Co

  13. Slide 13: Appendix

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Appendix

  14. Slide 14: Reconciliation of Non-GAAP Measures

    CONFIDENTIAL – MATERIAL NON-PUBLIC INFORMATION SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Reconciliation of Non-GAAP Measures 14 ________________________ (1) Includes $0.8 million and $0.2 million of accelerated depreciation in cost of sales and SG&A, respectively, related to restructuring charges in

Mallinckrodt — Debt Investor Presentation (August 2023) on 6ix